Fengxu Wu

1.8k total citations · 1 hit paper
39 papers, 1.4k citations indexed

About

Fengxu Wu is a scholar working on Molecular Biology, Organic Chemistry and Computational Theory and Mathematics. According to data from OpenAlex, Fengxu Wu has authored 39 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 17 papers in Organic Chemistry and 10 papers in Computational Theory and Mathematics. Recurrent topics in Fengxu Wu's work include Synthesis and biological activity (11 papers), Computational Drug Discovery Methods (10 papers) and Quinazolinone synthesis and applications (8 papers). Fengxu Wu is often cited by papers focused on Synthesis and biological activity (11 papers), Computational Drug Discovery Methods (10 papers) and Quinazolinone synthesis and applications (8 papers). Fengxu Wu collaborates with scholars based in China, Montenegro and United States. Fengxu Wu's co-authors include Guang‐Fu Yang, Ge‐Fei Hao, Zunnan Huang, Wen‐Chao Yang, Hong‐Yan Lin, Mengyuan Tan, Yuquan Zhou, Xiaoqing Wang, Xianhuan Shen and Haiyang Liu and has published in prestigious journals such as Nucleic Acids Research, Journal of Agricultural and Food Chemistry and Journal of Medicinal Chemistry.

In The Last Decade

Fengxu Wu

38 papers receiving 1.3k citations

Hit Papers

Computational Approaches in Preclinical Studies on Drug D... 2020 2026 2022 2024 2020 50 100 150 200

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fengxu Wu China 20 565 376 304 212 183 39 1.4k
Ivanka Tsakovska Bulgaria 18 434 0.8× 240 0.6× 411 1.4× 100 0.5× 70 0.4× 53 1.2k
Thomas Mietzner Germany 10 1.2k 2.1× 658 1.8× 1.2k 4.0× 164 0.8× 156 0.9× 11 2.1k
Natércia F. Brás Portugal 30 891 1.6× 341 0.9× 199 0.7× 85 0.4× 412 2.3× 85 2.4k
Huizhe Lu China 16 485 0.9× 241 0.6× 167 0.5× 128 0.6× 145 0.8× 61 946
Angelo Vedani Switzerland 27 1.1k 2.0× 419 1.1× 988 3.3× 279 1.3× 60 0.3× 74 2.1k
Kshatresh Dutta Dubey India 22 549 1.0× 257 0.7× 148 0.5× 79 0.4× 61 0.3× 79 1.3k
V. Ragunathan India 15 527 0.9× 252 0.7× 313 1.0× 157 0.7× 77 0.4× 35 1.2k
Eszter Hazai Hungary 23 801 1.4× 307 0.8× 286 0.9× 125 0.6× 85 0.5× 46 1.8k
Milton L. Hammond United States 28 666 1.2× 1.1k 2.8× 248 0.8× 90 0.4× 95 0.5× 73 2.3k
Ali Ryan United Kingdom 16 571 1.0× 140 0.4× 79 0.3× 55 0.3× 85 0.5× 26 983

Countries citing papers authored by Fengxu Wu

Since Specialization
Citations

This map shows the geographic impact of Fengxu Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fengxu Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fengxu Wu more than expected).

Fields of papers citing papers by Fengxu Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fengxu Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fengxu Wu. The network helps show where Fengxu Wu may publish in the future.

Co-authorship network of co-authors of Fengxu Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Fengxu Wu. A scholar is included among the top collaborators of Fengxu Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fengxu Wu. Fengxu Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ma, Junkai, et al.. (2025). Chalcone-Mediated and unexpected rearrangement preparation of 1H-pyrazol-furo[2,3-d]pyrimidine derivatives as potent antitumor agents. Journal of Molecular Structure. 1338. 142312–142312. 1 indexed citations
2.
He, Bo, Li‐Jun Chen, Tianzhu Zhang, et al.. (2025). Design and Syntheses of Proherbicides Targeting 4-Hydroxyphenylpyruvate Dioxygenase. Journal of Agricultural and Food Chemistry. 73(8). 4507–4517. 2 indexed citations
4.
Wu, Fengxu, et al.. (2024). AILDE Computer-Aided Discovery of Novel Ibuprofen–Coumarin Antitumor Lead Compounds Targeting Cyclooxygenase-2. ACS Omega. 9(39). 41021–41031. 2 indexed citations
6.
Yao, Jin, et al.. (2023). Novel Coumarin-furo[2,3-d]pyrimidinone hybrid derivatives as anticancer agents: Synthesis, biological evaluation and molecular docking. European Journal of Pharmaceutical Sciences. 188. 106520–106520. 9 indexed citations
7.
Wang, Qinyu, et al.. (2022). In Silico Methods for Identification of Potential Active Sites of Therapeutic Targets. Molecules. 27(20). 7103–7103. 43 indexed citations
9.
Gong, Yi, Fengxu Wu, Mingshu Wang, et al.. (2022). Discovery of 3-pyrazolyl-substituted pyrazolo[1,5-a]pyrimidine derivatives as potent TRK inhibitors to overcome clinically acquired resistance. European Journal of Medicinal Chemistry. 241. 114654–114654. 11 indexed citations
10.
Zhang, Xuting, et al.. (2021). In silico Methods for Identification of Potential Therapeutic Targets. Interdisciplinary Sciences Computational Life Sciences. 14(2). 285–310. 49 indexed citations
11.
Mei, Long‐Can, Fengxu Wu, Ge‐Fei Hao, & Guang‐Fu Yang. (2021). Protocol for hit-to-lead optimization of compounds by auto in silico ligand directing evolution (AILDE) approach. STAR Protocols. 2(1). 100312–100312. 9 indexed citations
12.
Wu, Fengxu, Yuquan Zhou, Xianhuan Shen, et al.. (2020). Computational Approaches in Preclinical Studies on Drug Discovery and Development. Frontiers in Chemistry. 8. 726–726. 248 indexed citations breakdown →
13.
Zhuo, Linsheng, Fengxu Wu, Mingshu Wang, et al.. (2020). Structure–activity relationship study of novel quinazoline-based 1,6-naphthyridinones as MET inhibitors with potent antitumor efficacy. European Journal of Medicinal Chemistry. 208. 112785–112785. 11 indexed citations
14.
Wu, Fengxu, Linsheng Zhuo, Fan Wang, et al.. (2020). Auto In Silico Ligand Directing Evolution to Facilitate the Rapid and Efficient Discovery of Drug Lead. iScience. 23(6). 101179–101179. 26 indexed citations
15.
Wang, Mingshu, et al.. (2020). Discovery of N-substituted-3-phenyl-1,6-naphthyridinone derivatives bearing quinoline moiety as selective type II c-Met kinase inhibitors against VEGFR-2. Bioorganic & Medicinal Chemistry. 28(12). 115555–115555. 15 indexed citations
16.
Huang, Xiaoting, Haiyang Liu, Fengxu Wu, et al.. (2019). A novel near-infrared fluorescent hydrogen sulfide probe for live cell and tissue imaging. New Journal of Chemistry. 43(18). 6848–6855. 32 indexed citations
17.
Kang, Weiming, et al.. (2019). Hydrophobicity-oriented drug design (HODD) of new human 4-hydroxyphenylpyruvate dioxygenase inhibitors. European Journal of Medicinal Chemistry. 166. 22–31. 22 indexed citations
18.
Wang, Fan, Fengxu Wu, Chengzhang Li, et al.. (2019). ACID: a free tool for drug repurposing using consensus inverse docking strategy. Journal of Cheminformatics. 11(1). 73–73. 57 indexed citations
19.
Hao, Ge‐Fei, Wen Jiang, Yuan‐Nong Ye, et al.. (2016). ACFIS: a web server for fragment-based drug discovery. Nucleic Acids Research. 44(W1). W550–W556. 102 indexed citations
20.
Wang, Dawei, Hong‐Yan Lin, Tao Chen, et al.. (2015). Synthesis and Herbicidal Activity of Triketone–Quinoline Hybrids as Novel 4-Hydroxyphenylpyruvate Dioxygenase Inhibitors. Journal of Agricultural and Food Chemistry. 63(23). 5587–5596. 97 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026